Cargando…
Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: A model agent for long-term complement inhibition in vivo
Despite its vital role in innate immunity, complement is involved in a number of inflammatory pathologies and has therefore become a therapeutic target. Most agents generated for anti-complement therapy have short half-lives in plasma, or have been of mouse or human origin, thereby limiting their us...
Autores principales: | Hepburn, Natalie J., Chamberlain-Banoub, Jayne L., Williams, Anwen S., Morgan, B. Paul, Harris, Claire L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Pergamon Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572221/ https://www.ncbi.nlm.nih.gov/pubmed/17651804 http://dx.doi.org/10.1016/j.molimm.2007.06.144 |
Ejemplares similares
-
Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis
por: Soltys, Jindrich, et al.
Publicado: (2012) -
Structures of the rat complement regulator CrrY
por: Roversi, Pietro, et al.
Publicado: (2011) -
Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
Publicado: (1978) -
Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023) -
Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)